ddp4 and glp 1 DPP4 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner Frontiers | Physiology and Pharmacology

Although no firm causality was demonstrated, and recent observational data are reassuring, it seems prudent to screen for depression and anxiety as common comorbidities in clinical practice [133, 143,144,145,146,147]

doi: 10.3892/or.2015.4138

doi: 10.3233/JAD-2010-1314 [DOI] [PMC free article] [PubMed] [Google Scholar] 152

Statistics in medicinereporting of subgroup analyses in clinical trials

Pancreatic safety of incretin-based drugsFDA and EMA assessment

Risk of Aborted Procedures and the Need to Repeat As a result of the increased risk of RGC with GLP-1 RAs and the subsequent increase in the risk of limited visibility and peri-procedural aspiration, the use of these agents can result in aborted procedures and the need to repeat for better visualization